A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M

BOOSTER: Osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M

First-generation EGFR tyrosine kinase inhibitors provide a significant clinical benefit for patients with advanced EGFR-mutant NSCLC. However, most patients ultimately develop disease progression, driven by the acquisition of a second T790M EGFR TKI resistance mutation.

Osimertinib (AZD9291) is an irreversible third-generation tyrosine kinase inhibitor of both EGFRm-sensitizing and T790M resistance mutants.

Bevacizumab is a humanized antibody targeting the vascular endothelial growth factor VEGF, which plays an important role in tumour angiogenesis.

A combination treatment that target both tumour cells and tumour microenvironment (such as angiogenesis) may be a promising strategy for further improving efficacy outcomes in patients with EGFRm (exon 19 deletion or exon 21 L858R) NSCLC following progression on EGFR TKI therapy and other lines of therapy.

The aim of the BOOSTER trial was to assess the efficacy of osimertinib plus bevacizumab versus osimertinib alone for patients with locally advanced or metastatic (stage IIIb-IVb) EGFRm NSCLC with a T790M resistance mutation at progression on prior EGFR TKI therapy.

Trial Scheme

Trial Information

Primary Endpoint:
Progression-free survival
Secondary Endpoints:
Objective response
Disease control
Overall survival
Adverse events
Target Sample Size:
154 Patients 
Final Accrual:
155 Patients
Protocol Release Date:
13 December 2016
Trial Activation Date:
05 April 2017
First Patient In:
31 May 2017
Accrual Closure Date:
21 February 2019
Global Trial Completion Date:
1 February 2024

Trial Organisation

Trial Chairs:
Solange Peters and Rolf Stahel 
Trial Co-Chairs:
Ross Soo and Ji-Youn Han
ETOP IBCSG Partners Foundation
Coordinating Group:
ETOP IBCSG Partners Foundation
Participating Groups:
Cancer Trials Ireland (CTI), Swiss Group for Clinical Cancer Research (SAKK) and Spanish Lung Cancer Group (SLCG)
Participating Countries: 
Europe: Ireland, Netherlands, Spain, Switzerland, South Korea Asia: Singapore
EudraCT number: 2016-002029-12
ClinicalTrials.gov: NCT03133546


ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland